NLRP3 and cardiac hypertrophy: Because there is no evidence to suggest that over-expressing miR-26a-5p in an otherwise wildtype background can also cause hypertrophy, targeting the NLRP3 inflammasome pathway will benefit the treatment of myocardial hypertrophy is unknown, and whether miR-26a-5p can regulate the NLRP3 pathway to prevent myocardial hypertrophy needs more research to verify.